Pharnext’s PXT3003 Featured in Multiple Presentations at the 6th International Charcot-Marie-Tooth and Related Neuropathy Consortium (CMTR) Meeting

Paris, September 1, 2016 – Pharnext, a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced that data related to its lead pleodrug PXT3003, being developed for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), will be presented in four posters at the 6th international Charcot-Marie-Tooth and Related neuropathy Consortium (CMTR) conference in Venice on September 8-10, 2016.

These four posters will be presented at two distinct poster sessions during the conference:

Poster Session #2 – Friday September 9th, 2016 – 1:30 to 2:30pm
Poster 20: “International, multi-center, randomized, double-blind, placebo-controlled Phase 3 study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth disease type 1A treated for 15 months.” Attarian S, et al.
Poster 21: “Baseline Analysis of PXT3003 Phase 2 Data Reveals Two Blood Early Candidate Biomarkers for Therapeutic Response in Charcot-Marie-Tooth Disease Type 1A.” Laffaire J, et al.

Poster Session #3 – Saturday September 10th, 2016 – 12:30 to 1:30pm
Poster 18: “An Online Survey of Neurologists about Charcot-Marie-Tooth Disease Type 1A.” Paoli X, et al.
Poster 29: “An Experimental Trial of an Early Onset Short-Term Treatment with a Combinational Drug (PXT3003) in the Charcot-Marie-Tooth 1A Rat Model.” Prukop T, et al.


About Pharnext
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: pleotherapy. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These “pleodrugs” offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, please visit www.pharnext.com